Benralizumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Trial Timeline
Apr 17, 2025 → Apr 3, 2028
NCT ID
NCT06512883About Benralizumab
Benralizumab is a phase 3 stage product being developed by AstraZeneca for Eosinophilic Granulomatosis With Polyangiitis (EGPA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06512883. Target conditions include Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444567 | Phase 3 | Recruiting |
| NCT07214753 | Pre-clinical | Recruiting |
| NCT06512883 | Phase 3 | Recruiting |
| NCT06465485 | Phase 3 | Active |
| NCT05273359 | Phase 2 | UNKNOWN |
| NCT05384938 | Approved | Completed |
| NCT05932849 | Pre-clinical | Completed |
| NCT04305405 | Phase 3 | Completed |
| NCT04102800 | Approved | Completed |
| NCT03928262 | Phase 1 | Completed |
| NCT03557307 | Phase 3 | Completed |
| NCT03327701 | Phase 3 | UNKNOWN |
| NCT03010436 | Phase 2 | UNKNOWN |
| NCT02918071 | Phase 3 | Completed |
| NCT02869438 | Phase 3 | Completed |
| NCT02821416 | Phase 3 | Completed |
| NCT02417961 | Phase 3 | Completed |
| NCT02130882 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Eosinophilic Granulomatosis With Polyangiitis (EGPA)